Informa

8:00am - 9:00am

Registration

SHOWING OF STREAMS

5:00pm - 5:05pm

Close of Pre-Conference Sessions

8:00am 9:00am (60 mins)

Registration

9:00am 5:00pm (480 mins)

Training Course: Introduction to Antibody Engineering

Introduction to Antibody Engineering

Add-on this pre-conference training course to your main conference registration package for an additional fee and gain a comprehensive over of antibody engineering in an easy to follow classroom setting to help you prepare for the main conference program. Training course registration begins at 8:30am.

TRAINING COURSE OVERVIEW

Today's wealth of knowledge of protein structures will be reviewed along with the genetics of diversity generation of antibodies, to give insights into the best strategies for improving protein function.There is particular emphasis on the choice of a functional assay to monitor effectively the changes in a desired property, and the use of functional enrichment steps where a library approach is employed. Not only is amino acid sequence amenable to engineering, but glycan structures and other modifications may also be engineered. The course will focus on the engineering and enhancement of antibodies and antibody-like scaffolds. Examples will include work on antibody fragment affinity improvement by 100-fold to low pM affinity. Also the engineering of bispecific antibodies by diverse approaches and the adaptation to generate Chimeric Antibody Receptor (CAR) constructs will be discussed. Expression platforms for producing antibodies for testing and for manufacture will also be covered. A background in biochemistry and molecular biology is useful, as the course is designed to progress rapidly from simple to advanced concepts.

COURSE AGENDA

  • Functions amenable to engineering: affinity, specificity, stability, solubility, immunogenicity
  • The measure of success: functional assays
  • Engineering by design
  • Engineering by random mutation
  • Designed libraries
  • Display technologies
  • Improving manufacturing by protein engineering methods
  • Glycosylation engineering - function and homogeneity
  • Other protein modifications
  • Immunogenicity engineering
  • Bispecific antibodies
  • Antibody-drug conjugates (ADCs)
  • CAR-T strategies
  • Expression of antibodies and fragments for discovery and testing
  • Manufacturing platforms for antibodies and fragments
  • Instructor David Bramhill, Ph.D. - Consultant, Bramhill Biological Consulting, LLC

1:00pm 1:15pm (15 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Workshop Moderator's Remarks

  • Moderator Andrew Bradbury, Ph.D. - Research Scientist and Group Leader, Los Alamos National Laboratories

1:15pm 1:45pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Phage Display Selection of Conformation-sensitive Single Domain Antibodies against Intact Cells

Single domain antibodies have a natural tendency to bind cavities and are often sensitive to conformational changes of their target. We are exploiting these properties and the power of phage display selection on intact cells to generate conformational sensors against difficult targets such as GPCRs of the mGluR family or RTKs of the EGFR family. Selection strategies and examples of applications will be discussed

  • Patrick Chames, Ph.D. - Principal Investigator, Cancer Research Center of Marseille (CRCM), INSERM

1:45pm 2:15pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Selection of Antibodies to Transiently Expressed Membrane Proteins Using Phage Display and Fluorescence-activated Cell Sorting

Membrane proteins make difficult targets for phage display panning. Using whole cells for panning provides the native structure, but is complicated by a low receptor density against a high background of irrelevant antigens.  Transient transfection of GFP-tagged membrane proteins, using alternating host cell lines, and combined with fluorescence-activated cell sorting, can be used to decrease these limitations while screening antibody phage libraries.

  • Martina Jones, Ph.D. - Operations Manager - National Biologics Facility and Deputy Director - ARC Training Centre for Biopharm, AIBN, The University of Queensland

2:15pm 2:45pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Antibodies to Challenging Receptor Targets through NGS and Cell-Based Antibody Phage Panning

Several receptor targets cannot be made as soluble proteins and others are problematic for discovery of antibodies that bind to native protein conformations. Cell-based phage panning can identify antibodies to such targets, but is inefficient, often producing low antibody diversity. We utilized next generation sequencing to improve the robustness of cell-based selections.


  • John Wheeler, Ph.D. - Principal Research Scientist, Janssen BioTherapeutics, Janssen R&D

2:45pm 3:15pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Networking Refreshment Break

3:15pm 3:45pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Signal Amplification Methods in Immunoassays and Cell Biology

Judicious use of antibody combinations can produce two-site ELISAs with great specificity. But even using high affinity antibodies, it may be difficult to detect very low levels of antigen in serum or tissue samples. In this case, some form of signal amplification can be used. A popular method exploits the use of peroxidase-labelled antibodies reacting with a tyramide-biotin derivative to generate a short-lived reactive product that biotinylates proteins in the immediate vicinity of the bound antibody. The biotin can then be detected using a suitable labelled streptavidin derivative. Since this is an enzyme-driven reaction, many biotin molecules can be deposited relative to the number of bound antibodies. Hence in principle, a major signal amplification is possible. However, these methods are no substitute for good high-affinity antibodies, and background signals can still be a problem. This talk will cover some of these issues and discuss other means of signal amplification. Finally, the use of tryamide-biotin in other applications such as proteomic proximity labelling will be discussed, to illustrate how these techniques, originally developed for immunoassays are beginning to receive much wider attention within the cell biology community.

  • Tony Jackson, Ph.D. - Senior Lecturer, Biochemistry, University of Cambridge

3:45pm 4:15pm (30 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Advances in Yeast Display Selections for Membrane Targets

The presentation will discuss advances in yeast display technologies to select binders to membrane targets in their intact cellular context. The impacts of ligand and target accessibility and valency, and other elements of selection design, on enrichment, affinity stringency, and target specificity will be discussed in the context of alternative scaffold ligand discovery.

  • Benjamin Hackel, Ph.D. - Chemical Engineering and Materials Science, University of Minnesota

4:15pm 5:00pm (45 mins)

Workshop A: Selecting Antibodies Against Cell-Surface Targets

Panel Discussion

  • Moderator Andrew Bradbury, Ph.D. - Research Scientist and Group Leader, Los Alamos National Laboratories
  • Panelist Patrick Chames, Ph.D. - Principal Investigator, Cancer Research Center of Marseille (CRCM), INSERM
  • Panelist Benjamin Hackel, Ph.D. - Chemical Engineering and Materials Science, University of Minnesota
  • Panelist Tony Jackson, Ph.D. - Senior Lecturer, Biochemistry, University of Cambridge
  • Panelist Martina Jones, Ph.D. - Operations Manager - National Biologics Facility and Deputy Director - ARC Training Centre for Biopharm, AIBN, The University of Queensland
  • Panelist John Wheeler, Ph.D. - Principal Research Scientist, Janssen BioTherapeutics, Janssen R&D

1:00pm 3:00pm (120 mins)

Workshop B: Antibody Developability

Antibody Developability

This workshop will provide an overview of the nuts and bolts of antibody development and developability assessment to help you accelerate antibody drugs to the clinic. it will explore various strategies to discovering and designing antibodies with properties that are more likely to be successful in development. Building in "developability" and "manufacturability" assessments is crucial in any antibody discovery program, and this workshop will discuss case studies and lessons learned from a variety of antibody projects. Developability considerations to be discussed include: developability modeling and prediction, developability assessment methods, biophysical properties and PK, delivery, cell line development and more.

The presentation times below are for display purposes only and are subject to change. This workshop will run from 1:00pm-5:00pm.

  • Moderator Mark Chiu, Ph.D. - Associate Director of Development, Janssen R&D

3:00pm 3:30pm (30 mins)

Workshop B: Antibody Developability

Antibody-display Libraries in Mammalian Cells Created Using CRISPR/Cas9 and TALE Nucleases

Using directed integration of antibody genes by CRISPR/Cas9 and TALE nucleases we have constructed large libraries in mammalian cells containing a single antibody gene/cell. This has permitted construction of populations of millions of monoclonal stable cell lines displaying antibodies on their surface from which novel binders including IgG formatted antibodies, have been isolated. This together with transcriptional "normalization" from a single locus and expression in cell lines used for production enable aspects of developability to be incorporated during antibody discovery.

  • John McCafferty, Ph.D. - CEO and Founder, IONTAS

3:30pm 4:00pm (30 mins)

Workshop B: Antibody Developability

Biophysical Properties of the Therapeutic Antibody Landscape

  • Max Vasquez - Vice President, Computational Biology, Adimab LLC

4:00pm 4:30pm (30 mins)

Workshop B: Antibody Developability

Fc Engineering for Improved Developability and Retained Biological Activity

Modifications of the IgG Fc have allowed for serum persistence and immune engagement to become tunable properties for therapeutic mabs and Fc fusions. Nevertheless, these mutation combinations are rarely "plug-and-play" and can introduce developability problems not present in the parental antibody. This talk will focus on strategies to assess the stability of Fc mutants and outline our engineering approach to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.

  • Speaker M. Jack Borrok, Ph.D. - Scientist II, MedImmune

4:30pm 5:00pm (30 mins)

Workshop B: Antibody Developability

Antibody Engineering with Optimized Developability - Modulation of Effector Function

While biological activity always trumps the developability assessments, there is also the need to ensure adequate productivity to meet the future commercial demand and product quality that leads to favorable safety and efficacy. This presentation will review engineering strategies for modulating the antibody effector function and discuss engineering of an IgG scaffold with optimized developability. Extensive biophysical analyses and pharmacokinetic studies were utilized to assess the developability of the engineered scaffold.

  • Guna Kannan, Ph.D. - Director, Biologics-Antibody Engineering, Pharmaceutical Development, Santen, Inc.

5:00pm 5:05pm (5 mins)

Close of Pre-Conference Sessions

* 活动内容有可能不事先告知作更动及调整。